{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Iodine_I_131_Tositumomab",
  "nciThesaurus": {
    "casRegistry": "192391-48-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.",
    "fdaUniiCode": "K1KT5M40JC",
    "identifier": "C2444",
    "preferredName": "Iodine I 131 Tositumomab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129819",
      "C1511"
    ],
    "synonyms": [
      "131-I-Anti-B1 Monoclonal Antibody",
      "Bexxar",
      "I 131 Monoclonal Antibody Anti-B1",
      "I 131 Tositumomab",
      "I131-MOAB-B1",
      "Iodine I 131 MOAB Anti-B1",
      "Iodine I 131 Monoclonal Antibody Anti-B1",
      "Iodine I 131 Tositumomab",
      "Iodine-131 Anti-B1 Antibody",
      "Iodine-131 Anti-CD20 Monoclonal Antibody",
      "Iodine-131 Tositumomab",
      "TOSITUMOMAB I-131",
      "iodine I 131 tositumomab"
    ]
  }
}